Kyle Rasbach's most recent trade in Lexeo Therapeutics Inc. was a trade of 245,250 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics Inc. | Kyle Rasbach | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 245,250 | 245,250 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc. | Kyle Rasbach | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 40,875 | 40,875 | - | 0 | Common Stock |